# *Andrology*

## **Effect of Pentoxifylline on Tumor Suppressor and Proto-Oncogene Apoptosis in Sperm**

David T. Maxwell,<sup>1</sup> John D. Jacobson,<sup>1</sup> Alan King,<sup>1</sup> and Philip J. Chan<sup>1,2,3</sup>

*Submitted October 22, 2001; accepted February 7, 2002*

*Purpose*: Pentoxifylline (PTX), a methylxanthine phosphodiesterase inhibitor reduces superoxide anions responsible for DNA apoptosis. The null hypothesis was that PTX was equally effective in reducing damage to specific cell genes. The objective was to determine the DNA integrity of the *BRCA1* tumor suppressor gene and the c-*myc* proto-oncogene after PTX. *Methods***:** Sperm (64 samples, 4 patients) were preincubated in either 0 (control) or 3.6 mM PTX (30 min), washed and incubated for 4 h at either 37 or 40◦C heat shock activation. Single primer polymerase chain reactions (PCR) were carried out on lysed sperm targeting either *BRCA1* exon 11 or c-*myc* exon 1. Control single-stranded DNA (ssDNA) were stained with 9  $\mu$ M Hoechst 33342 (blue) while PTX-treated ssDNA were stained with SYBR Gold (green). Nytran membrane discs with control ssDNA were hybridized to PTX-derived ssDNA. Fluorescent images stored in a microarray design were analyzed using ANOVA and Students' *t*-test for ( $P < 0.05$ ) significance.

*Results*: *BRCA1* integrity was higher with PTX pretreatment (93.3 + 10.4 vs. control 50.5 + 9.2; mean  $+$  SEM). In contrast, there was no difference in c-*myc* integrity (56.8  $+$  9.0 vs. 41.7  $+$ 6.4). Sense or antisense primers gave similar DNA fragmentation results.

*Conclusions***:** The data showed PTX pretreatment protected *BRCA1* but not c-*myc* suggesting that PTX did not equally protect different cell genes. A possible explanation was that protooncogenes had more fragile sites. The study involved the DNA disc chip assay to assess separate PCR-amplified sense and antisense strands. The results suggested that both strands were equally affected by PTX pretreatment.

**KEY WORDS:** Comparative genomic hybridization; pentoxifylline; proto-oncogene; spermatozoa; tumor suppressor gene.

#### **INTRODUCTION**

Pentoxifylline (PTX), a methylxanthine phosphodiesterase inhibitor, increases cyclic adenosine 3':5' monophosphate (cAMP) intracellularly (1,2), reduces superoxide anions and inhibit tumor-necrosis

factor—alpha (TNF-alpha) responsible for DNA fragmentation and apoptosis or programmed cell death (3–7). PTX has been used to stimulate sperm motility and improve fertilization (2). Furthermore, PTX has been used in clinical procedures to scavenge reactive oxygen species and reduce lipid peroxidation associated sperm membrane damage and DNA apoptosis (4,8–10). While most studies focus on the assessment of the entire genome for DNA damage, it is uncertain if the integrity of each specific gene is equally affected by PTX-mediated inhibition of apoptosis. The null hypothesis was that PTX was equally effective in reducing damage to specific cell genes. The objective was to determine the DNA

<sup>1</sup> Department of Gynecology and Obstetrics, Loma Linda University School of Medicine, Loma Linda, California.

<sup>&</sup>lt;sup>2</sup> Department of Physiology and Pharmacology, Loma Linda University School of Medicine, Loma Linda, California.

<sup>&</sup>lt;sup>3</sup> To whom correspondence should be addressed at Loma Linda University Center for Fertility and In Vitro Fertilization, 11370 Anderson Street, Suite 3950, Loma Linda, California 92354; e-mail: pchann@yahoo.com.

integrity of the *BRCA1* tumor suppressor gene and the c-*myc* proto-oncogene in sperm after PTX pretreatment and followed by heat shock activation. The information obtained would help to stimulate further studies examining the differential effect of chemical agents on the integrity of different genes.

## **MATERIALS AND METHODS**

#### **Specimen Preparation**

The sperm cells were from male partners of infertile couples attending an assisted reproductive technologies program. The spermiograms of the male patients were considered normal with normal concentration, total motility and normal morphology as assessed through basic semen analyses. Data from patients that involved epididymal sperm aspiration or donor sperm were not included in the study. A total of 64 washed specimens from four cases were evaluated. This study that was based on the multiple cell comet assay was approved by the Loma Linda University Institutional Review Board.

Each sperm specimen was divided into two portions and washed using either the swim-up (control) or pentoxifylline wash procedure (11). The swim-up procedure consisted of layering a 1 mL volume of HEPES-based human tubal fluid culture medium with 5% human serum albumin (mHTF, Irvine Scientific, Santa Ana, CA) over on top of 1 mL of semen in a centrifuge tube. The tubes were placed in a 37◦C waterbath for 30 min and the bottom layer of semen pipetted out and disposed. The remaining tubes of culture medium containing the motile sperm were centrifuged (300*g*, 10 min), resuspended in 0.4 mL mHTF and labeled as the swim-up group.

The pentoxifylline wash procedure involved mixing 1 mL of each semen specimen with 1 mL of pentoxifylline (Sigma Chemicals, St. Louis, MO) dissolved in mHTF medium to obtain a 3.6 mM final concentration. Each mixture was incubated for 30 min at 37◦C in air before being layered over the 90:45% silane colloid layers (Isolate, Irvine Scientific, Santa Ana, CA) in a centrifuge tube and centrifuged at 300*g* for 10 min (11). The bottom 90% layer was removed, mixed with an equal volume of mHTF medium and centrifuged (300*g*, 10 min). Each pellet of sperm was resuspended in 0.4 mL mHTF medium and labeled as the pentoxifylline group.

A mild heat shock treatment was applied to each tube of swim-up or pentoxifylline-treated sperm. This consisted of incubating the tubes of sperm at 40◦C in

air for 4 h (12). A second set of washed sperm was kept at 37◦C in air for 4 h as the unheated control. After 4 h, the sperm cells were stored frozen at −30◦C for several weeks and thawed for the DNA assays. The integrity of the tumor-suppressor gene, *BRCA1* and the proto-oncogene, c-*myc*, were assessed through a novel DNA disc chip assay based on comparative genomic hybridization (described below). These genes were selected based on the opposing functions of *BRCA1* and c-*myc* genes, and on the experience with polymerase chain reaction (PCR) primers for these genes at this laboratory.

## **The DNA Disc Chip Assay**

The DNA disc chip assay procedure was as follows: The frozen heat-treated and control sperm cells were thawed at room temperature for 10 min. The sperm were centrifuged at 3000*g* for 1 min to remove the culture media. Each resultant pellet was resuspended in 4◦C alkaline lysis buffer (1% *N*-Lauroylsarcosine, 1.0 M Tris–HCl, pH 7.5, 0.5 M EDTA, 0.3 M mercaptoethanol, pH adjusted to  $>10$  with sodium hydroxide pellets) for 20 min with periodic vortexing to release the sperm DNA. The tubes of sperm DNA were then placed in a PCR thermal cycler and heated at 94◦C for 5 min to denature the DNA into single strands similar to the "hot start" PCR protocol. Single-stranded DNA (ssDNA) were generated using the single primer PCR procedure. The PCR amplifications of sperm DNA involved either the sense or antisense primer targeting either the protein-coding region of *BRCA1* (13) at exon 11 (434 base pair, bp) or the regulatory region (14) of c-*myc* exon 1 (256 bp).

The DNA staining procedure was carried out in diffuse lighting or darkened room. The control (swim-up or pentoxifylline-treated at 37◦C) sperm ssDNA (derived from sense or antisense primers) were stained in 9  $\mu$ M bisbenzimide (Hoechst 33342, Sigma Chemicals, St. Louis, MO) for 5 min and centrifuge-washed twice to remove excess stain (3000*g* for 1 min). The ssDNA (derived from sense or antisense) from heat shocked sperm (swim-up or pentoxifylline-treated at 40◦C) were stained in 1:10,000 diluted SYBR Gold stock stain (Molecular Probes, Eugene, OR) for 5 min and excess stain removed as recommended by the manufacturer. It was unnecessary to adjust DNA concentration in the tubes due to the matched control-test design and saturation of the positive-charged miniature disc.

The tiny round discs used in the DNA disc chip assay were made by pressing a 2 mm Acupunch biopsy  $PTX$ 

Sense

Antisense



**Fig. 1.** A DNA disc chip assay showing bright fluorescent *BRCA1* exon 11 single-stranded DNA (ssDNA) of both sense and antisense strands in the hybridized membrane discs (2 mm diameter) associated with DNA integrity in sperm cells pretreated with 3.6 mM pentoxifylline (PTX) and heat shock treated at  $40^{\circ}$ C for 4 h. In contrast, the ssDNA of *BRCA1* after swimup processing (control) and the ssDNA of c-*myc* exon 1 of sperm exhibited low fluorescence suggesting DNA fragmentation and apoptosis. All control matching ssDNA embedded on the discs were analyzed and found to have similar fluorescence. Each digitized image was reduced by 80%, cut and pasted on to an image of a multiwell tray to form a microarray of images for storage, comparison, analysis, and presentation purposes.

punch pen (Acuderm, Ft. Lauderdale, FL) into the Nytran (Schleicher & Schuell, Keene, NH) membrane sheet and using a plastic stylet to expel the round discs. The size of the disc was chosen to fit the  $40\times$ magnification of the fluorescent microscope used in this lab. The discs could be attached into the wells of a microtiter plate to process greater volume of samples, similar to a microarray design. For this study, each disc was held using a pair of microforceps and first dipped into the tube of control  $(37°C)$  ssDNA (Hoechst 33342, blue fluorescence) for a few seconds and blotting off the excess. Then, the disc was dropped into the tube of test (40◦C) ssDNA (Sybr Gold, greengolden fluorescence). This process was repeated several times to obtain replicated data points.

Each tube with submerged discs was allowed to hybridize for 10–20 s. Several discs were removed using a pair of microforceps, and lined up on a glass slide to form a DNA chip. Each glass slide with the DNA discs was examined using an ultraviolet (UV) epifluorescent microscope at  $40\times$  magnification. The fluorescent images were captured by placing an inexpensive QuickCam Pro camera (Logitech, Fremont, CA) over the microscope eyepiece and saving the 640  $\times$ 480 pixels images to hard disk (Fig. 1). For comparison purposes, the color images were computer-cut and pasted on to a photo of a 50-well microtiter plate in a microarray design using the Microsoft Paint program. The images were converted to grey-scale and the pixel intensity of each disc analyzed using Paint Shop Pro 6 software (Jasc Software, Eden Prairie, MN). Greater damage of ssDNA was observed as a lower pixel intensity (green-golden fluorescent) of the disc due to lack of pairing or mismatch with the control ssDNA.

#### **Statistical Analysis**

The pixel intensity of each fluorescent disc containing hybridized DNA was obtained from the computer imaging software and expressed as mean  $\pm$  SEM (standard error of the mean). The pixel intensity of each disc from heat-treated (40◦C) sperm DNA were matched or paired with the pixel intensity of corresponding internal calibration control (37◦C) sperm. Analysis of variance (ANOVA) followed by significance testing of the means using the Students' *t*-test statistic were used. A value of  $P < 0.05$  was considered significant.

## **RESULTS**

The sperm specimens used for the present study (Table I) were considered normal in accordance with the values set by the 1999 fourth edition of the World Health Organization (WHO) Semen Analysis Manual (15). There were no remarkable differences between the postwash motilities of the control swim-up from semen group and the PTX pretreated group.

The integrity of the *BRCA1* gene was almost twofold greater  $(P < 0.05)$  in sperm with PTX pretreatment (93.3  $\pm$  10.4 vs. 50.5  $\pm$  9.2) when compared with control sperm (Table II). In contrast, c-*myc*  $(56.8 \pm 9.0 \text{ vs. } 41.7 \pm 6.4)$  gene integrity was similar for both the PTX pretreatment and control groups. Interestingly, the antisense strand of *BRCA1* appeared to be less stable than the sense strand while the opposite was observed for the c-*myc* gene. Statistically, the sense and antisense data were considered similar in terms of intensity of DNA fragmentation. Blank Nytran membrane discs were used in

**Table I.** Basic Sperm Parameters and Motilities After Processing Through Either the Swim-Up from Semen (Control) or Pentoxifylline (3.6 mM) Treatment

Parameter	Results $mean \pm SEM$ )	WHO normal reference $(15)$
Concentration (million/mL) Total motility $(\%)$ Strict normal morphology $(\%)$ Postwash total motility Swim-up from semen $(\%)$ Pentoxifylline treatment (%)	$49.3 \pm 1.0$ $62.8 + 5.2$ $11.3 \pm 1.8$ $82.3 + 7.5$ $85.5 + 4.4$	$>$ 20 million/mL $> 50\%$ motile $>4\%$ normal

		Pixel intensities of fluorescent discs (mean $+$ SEM)			
Treatment	N	Antisense ssDNA of heated sperm paired with control sense ssDNA on disc	Sense ssDNA of heated sperm paired with control antisense ssDNA on disc	Cumulative data of heated ssDNA paired with control ssDNA	
<i>BRCA1</i> exon 11					
Swim-up control	8	$50.5 \pm 18.7$	$50.0 \pm 10.7$	$50.5 \pm 9.2$	
Pentoxifylline	8	$86.5 + 8.8^a$	$100.1 \pm 21.8^a$	$93.3 \pm 10.4^{\circ}$	
Negative control	4	n/a	n/a	$25.3 \pm 1.5$	
c- <i>myc</i> exon 1					
Swim-up control	8	$47.0 \pm 11.5$	$34.7 \pm 11.8$	$41.7 \pm 6.4$	
Pentoxifylline	8	$71.0 \pm 14.0$	$42.6 \pm 8.2$	$56.8 \pm 9.0$	
Negative swim-up	4	n/a	n/a	$25.6 \pm 3.0$	

**Table II.** A Comparative Genomic Hybridization DNA Disc Chip Assay of the Tumor Suppressor Gene, *BRCA1*, and the Proto-Oncogene, c-*myc*, in Sperm Cells with and Without Pentoxifylline (3.6 mM) Pretreatment

*a* Different from control.  $P < 0.05$ .

the determination of background fluorescence for the negative controls and did not have sense or antisense data.

## **DISCUSSION**

The methylxanthine phosphodiesterase inhibitor, PTX [1-9[5-oxohexyl]-3-7-dimethylxanthine), has been reported to stimulate sperm motility  $(1,2)$ by increasing intracellular cyclic adenosine  $3'$ :5' monophosphate (cAMP) and by reducing superoxide anion and reactive oxygen species (ROS), which damage DNA (9,10). Pretreatment of asthenozoospermic or slow moving sperm with PTX has been shown to improve in vitro fertilization of oocytes (2). Consistent with the known protective effect of PTX on DNA, sperm pretreated with PTX also showed less DNA damage in specific genes after heat shock treatment. Specifically, the tumor suppressor gene, *BRCA1*, remained relatively intact in PTX pretreated sperm when compared with untreated sperm.

However, the proto-oncogene, c-*myc*, was not protected by PTX pretreatment. The results suggested that PTX did not act with equal efficacy in protecting different genes, in this case, genes involved with cell proliferation and growth. One possible explanation was that proto-oncogenes might have more fragile sites that are prone to damage (16) or that the DNA repair mechanisms are absent or slow reacting for proto-oncogenes. The c-*myc* proto-oncogene is located on the long arm of Chromosome 8. The proto-oncogenes include c-*myc*, c-*fos* and c-*jun*, and are nuclear proto-oncogenes involved in sperm function (17), and mediate the action of growth factors during cell proliferation (18). The protooncogenes code for nuclear proteins that regulate

DNA replication and RNA transcription during increased cell proliferation and differentiation (19). Tumor suppressor genes such as *BRCA1* (20–26) oppose the proliferation and growth directives of proto-oncogenes. The *BRCA1* gene is located on the long arm of Chromosome 17 and mutations of this gene are associated with breast, ovarian, prostate, and colon cancers (27).

The mechanism of PTX action involves inhibiting apoptosis or programmed cell death characterized by DNA fragmentation (28). PTX has been reported to interfere with lipid signaling of cytokines and inhibit tumor-necrosis factor—alpha (TNF-alpha) which is linked to the Caspase 3 enzyme for apoptosis (6). However, the results showing differences in PTX action on DNA integrity depending on gene type suggest an alternate apoptotic pathway unaffected by PTX. The differential protective effect of PTX on specific genes is important and suggest that apoptosis studies that focus on selected genes may miss important DNA alterations in other parts of the genome.

In this study, the DNA disc chip assay was utilized to assess the integrity of the DNA fragments produced by PCR amplification. The assay was simple and costeffective for gene analysis and permitted small laboratories to take part in the exciting fields of comparative genomic hybridization (29) and microarray analysis (30). The principle of this fluorescent assay was based on undamaged test DNA hybridizing with control DNA located on a membrane disc similar to the Southern blot (31). Intact test DNA exhibits maximal fluorescence in contrast to damaged or mutated test DNA that fails to hybridize efficiently and thus exhibit reduced fluorescence. Drawbacks of the assay included the requirement of a fluorescent microscope, a computer, and a digital camera. More studies

#### **Pentoxifylline Effect on Genes 283**

are needed to expand the capabilities of the assay to include RNA expression analysis.

## **REFERENCES**

- 1. Stefanovich V: Effect of 3,7-dimethyl-1-(5-oxohexyl)-xanthine and 1-hexyl-3,7-dimethyl-xanthine on cyclic AMP phosphodiesterase of the human umbilical cord vessels. Res Commun Chem Pathol Pharmacol 1973;5:655–662
- 2. Yovich JL: Pentoxifylline: Actions and applications in assisted reproduction. Hum Reprod 1993;8:1786–1791
- 3. Van Furth AM, Verhard-Seijmonsbergen EM, van Furth R, Langermans JA: Effect of lisofylline and pentoxifylline on the bacterial-stimulated production of TNF-alpha, IL-beta IL-10 by human leucocytes. Immunology 1997;91:193–196
- 4. Gavella M, Lipovac V, Marotti T: Effect of pentoxifylline on superoxide anion production by human sperm. Int J Androl 1991;14:320–327
- 5. Bessler H, GilGal R, Djaldetti M, Zahavi I: Effect of pentoxifylline on the phagocytic activity, cAMP levels, and superoxide anion production by monocytes and polymorphonuclear cells. J Leukoc Biol 1986;40:747–754
- 6. Mundle SD, Reza S, Ali A, Mativi Y, Shetty V, Venugopal P, Gregory SA, Raza A: Correlation of tumor necrosis factor alpha (TNF alpha) with high caspase 3-like activity in myelodysplastic syndromes. Cancer Lett 1999;140:201–207
- 7. Peeker R, Abramsson L, Marklund SL: Superoxide dismutase isoenzymes in human seminal plasma and spermatozoa. Mol Hum Reprod 1997;3:1061–1066
- 8. Aitken RJ, Harkiss D, Buckingham DW: Analysis of lipid peroxidation mechanisms in human spermatozoa. Mol Reprod Dev 1993;35:302–315
- 9. Twigg J, Fulton N, Gomez E, Irvine DS, Aitken RJ: Analysis of the impact of intracellular reactive oxygen species generation on the structural and functional integrity of human spermatozoa: Lipid peroxidation, DNA fragmentation and effectiveness of antioxidants. Hum Reprod 1998;13:1429–1436
- 10. Lopes S, Jurisicova A, Sun JG, Casper RF: Reactive oxygen species: Potential cause for DNA fragmentation in human spermatozoa. Hum Reprod 1998;13:896–900
- 11. Pang SC, Chan PJ, Lu A: Effects of pentoxifylline on sperm motility and hyperactivation in normozoospermic and normokinetic semen. Fertil Steril 1993;60:336–343
- 12. Alvarez JG, Minaretzis D, Barrett CB, Mortola JF, Thompson IE: The sperm stress test: A novel test that predicts pregnancy in assisted reproductive technologies. Fertil Steril 1996;65:400–405
- 13. Smith TM, Lee MK, Szabo CI, Jerome N, McEuen M, Taylor M, Hood L, King MC: Complete genomic sequence and analysis of 117 kb of human DNA containing the gene BRCA1. Genome Res 1996;6:1029–1049
- 14. Cole MD: The myc oncogene: Its role in transformation and differentiation. Annu Rev Genet 1986;20:361–384
- 15. World Health Organization: WHO Laboratory Manual for the Examination of Human Semen and Semen-Cervical Mucus Interaction, 4th ed. Cambridge, UK, The Press Syndicate of the University of Cambridge, 1999, pp. 19–23, 60–61
- 16. Yunis JJ, Soreng AL, Bowe AE: Fragile sites are targets of diverse mutagens and carcinogens. Oncogene 1987;1:59– 69
- 17. Naz RK, Kumar G, Minhas BS: Expression and role of c-*myc* protooncogene in murine preimplantation embryonic development. J Assist Reprod Genet 1994;11:208–216
- 18. Adamson ED: Oncogenes in development. Development 1987;99:449–471
- 19. Duffy MJ: Cellular oncogenes and suppressor genes as prognostic markers in cancer. Clin Biochem 1993;26:439–447
- 20. Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, King MC: Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990;250:1684–1689
- 21. Black DM, Solomon E: The search for the familial breast/ovarian cancer gene. Trends Genet 1993;9:22–26
- 22. Narod SA, Feunteun J, Lynch HT, Watson P, Conway T, Lynch J, Lenoir GM: Familial breast-ovarian cancer locus on chromosome 17q12-q23. Lancet 1991;338:82–83
- 23. Easton DF, Ford D, Bishop DT: Breast and ovarian cancer incidence in BRCA1-mutation carriers: Breast Cancer Linkage Consortium. Am J Hum Genet 1995;56:265–271
- 24. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu O, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Ghulami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, Narod S, Bristow PK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barrett JC, Lewis C, Neuhausen S, Cannon-Albright L, Goldgar D, Wiseman R, Kamb A, Skolnick MH: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266: 66–71
- 25. Steichen-Gersdorf E, Gallion HH, Ford D, Girodet C, Easton DF, DiCioccio RA, Evans G, Ponder MA, Pye C, Mazoyer S, Noguchi T, Karengueven F, Sobol H, Hardouin A, Bignon Y-J, Piver MS, Smith SA, Ponder BAJ: Familial site-specific ovarian cancer is linked to BRCA1 on 17q12-21. Am J Hum Genet 1994;55:870–875
- 26. Gudas JM, Nguyen H, Li T, Cowan KH: Hormone dependent regulation of BRCA1 in human breast cancer cells. Cancer Res 1995;55:4561–4565
- 27. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE: Risks of cancer in BRCA1-mutation carriers: Breast Cancer Linkage Consortium. Lancet 1994;343:692–695
- 28. Belloc F, Jaloustre C, Dumain P, Lacombe F, Lenoble M, Boisseau MR: Effect of pentoxifylline on apoptosis of cultured cells. J Cardiovasc Pharmacol 1995;25(Suppl 2):s71– s74
- 29. Kallioniemi A, Kallioniemi O-P, Sudar D, Rutovitz D, Gray JW, Waldman F, Pinkel D: Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 1992;258:818–821
- 30. Schena M, Shalon D, Davis RW, Brown PO: Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995;270:467–470
- 31. Southern EM: Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol 1975;98:503–517